Drug Type Small molecule drug |
Synonyms Nalfurafine, Nalfurafine hydrochloride (JAN/USAN), Nopicor + [10] |
Target |
Mechanism κ opioid receptor agonists(Kappa opioid receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (21 Jan 2009), |
RegulationOrphan Drug (KR) |
Molecular FormulaC28H32N2O5 |
InChIKeyXGZZHZMWIXFATA-UEZBDDGYSA-N |
CAS Registry152657-84-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06405 | Nalfurafine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pruritus | JP | 21 Jan 2009 | |
Pruritus | JP | 21 Jan 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic liver disease | Phase 3 | CN | 13 Oct 2023 | |
Chronic liver disease | Phase 3 | CN | 13 Oct 2023 | |
Chronic liver disease | Phase 3 | CN | 13 Oct 2023 | |
Pruritus | Phase 3 | CN | 17 Dec 2021 | |
Uremic pruritus | Phase 3 | CN | 07 Sep 2020 | |
Uremic pruritus | Phase 2 | CN | 07 Sep 2020 | |
Kidney Failure, Chronic | Phase 2 | US | 01 Sep 2012 | |
Kidney Failure, Chronic | Discovery | US | 01 Sep 2012 | |
Cancer Pain | Discovery | US | - | - |
Dermatitis, Atopic | Discovery | JP | - | - |
Phase 2 | 45 | (MT-9938 2.5μg) | lhfejallzb(xdighkxlbm) = tqmsidtyfd iuryndqlyb (gtrotcvqye, juidnqtwpm - uadogjlguu) View more | - | 09 Feb 2022 | ||
(MT-9938 5μg) | lhfejallzb(xdighkxlbm) = gfdqcyogdy iuryndqlyb (gtrotcvqye, kjnbmculgn - gfiwaxhkzx) View more |